Braveheart Bio Inc. (BRVE) IPO — Listing Details

Braveheart Bio Inc. (BRVE)

This listing has debuted. The live 5-factor QL signal switches on as soon as the engine has enough trading history.

About Braveheart Bio Inc.

We are a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor ("CMI"), that we are developing for the treatment of obstructive HCM ("oHCM") and non-obstructive HCM ("nHCM").

From Braveheart Bio Inc.'s Form 424B4 filed with the SEC on 2026-08-06. The issuer's own words — QuantLogix does not paraphrase it.

Industry

Pharmaceutical Preparations

Headquarters

San Francisco, CA

Incorporated in

Delaware

Fiscal year ends

December 31

SEC filer

CIK 0002131524

Non-accelerated filer Smaller reporting company Emerging growth company

The offering

Ticker

BRVE

Exchange

XNAS

Listed

2026-08-0637d ago

Offer price

$18

Deal size

$383M

gross proceeds

Shares offered

21,250,000

Shares outstanding

70,652,838

after the offering

Implied market cap

$1.3B

at the final offer price

Public float

30.1%

of shares outstanding

Share class

Ordinary Shares

Financials, as filed

The audited financial statements for this issuer are in its Form 424B4 filed 2026-08-06. QuantLogix only publishes figures it can read directly from the filing.

QL Listing Score — the prospectus, scored

71/100

Strong · low confidence

The evolution of the private-company QL Score at the point of listing: four evidence pillars read deterministically from the registration statement — growth, revenue quality, technology and risk — weights frozen per version (v1.1.0), pillars with no evidence excluded and reweighted, never defaulted.

Growthno evidence — excluded

Revenue qualityno evidence — excluded

Technology75

technology-language density 17.0/10k words (lexical indicator, not a technical audit)

Risk70

Foundationno evidence — excluded

✓ No going-concern doubt✓ No material weakness disclosed✓ Single share class✓ No customer-concentration flag◆ Emerging growth company (reduced disclosure)

From Braveheart Bio Inc.'s Form 424B4 filed with the SEC on 2026-08-06. Extraction is deterministic — the same filing always produces the same score; 485k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.

Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.